Streetbeat News

DICE

DICE Therapeutics Inc

Industry

Medicinal and Botanical Manufacturing

Open

47.59

Mkt cap

2.3B

Volume

4.3M

High

47.83

P/E Ratio

-21.91

52-wk high

47.90

Low

47.46

Div yield

N/A

52-wk low

15.08

Surgalign Holdings shares dropped by around 75% after filing for Chapter 11 bankruptcy. Other stocks experienced significant gains and losses during Tuesday's mid-day session, with Airspan Networks, Evelo Biosciences, and VCI Global among the top gainers.

Portfolio Pulse from Lisa Levin

June 20, 2023 | 5:07 pm

Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on DICE Therapeutics (NASDAQ:DICE) and raises the price target from $38 to $48.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 4:55 pm

Cantor Fitzgerald analyst Prakhar Agrawal downgraded DICE Therapeutics (NASDAQ:DICE) from Overweight to Neutral and lowered the price target from $58 to $48.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 4:44 pm

US stocks traded lower with Dow Jones dropping over 300 points. DICE Therapeutics shares spiked 37% after Eli Lilly agreed to acquire the company for $48 per share in cash. Housing starts in the US surged 21.7% month-over-month in May.

Portfolio Pulse from Lisa Levin

June 20, 2023 | 4:29 pm

Canaccord Genuity analyst Edward Nash downgrades DICE Therapeutics (NASDAQ:DICE) from Buy to Hold and lowers the price target from $71 to $48.

Portfolio Pulse from richadhand@benzinga.com

June 20, 2023 | 3:48 pm

Eli Lilly (NYSE:LLY) has announced the acquisition of DICE Therapeutics (NASDAQ:DICE) for $2.40 billion in cash, expected to be completed in Q3 of 2023. Eli Lilly is a drug firm focused on neuroscience, cardiometabolic, cancer, and immunology, while DICE Therapeutics is a biopharmaceutical company developing oral therapeutic candidates for chronic diseases.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 3:10 pm

Eli Lilly agreed to acquire DICE Therapeutics for $48 per share, causing DICE's stock to climb 37.7%. Quotient Technology announced a combination with Neptune Retail Solutions, leading to a 16.4% surge in its shares. Cano Health's CEO Dr. Marlow Hernandez stepped down, and Mark Kent was appointed as interim CEO, resulting in a 12.1% gain in the company's stock.

Portfolio Pulse from Lisa Levin

June 20, 2023 | 2:22 pm

US stocks traded mixed with Dow Jones dropping over 150 points, while housing starts surged 21.7% MoM in May. Utilities shares jumped by 1.2%, with ReNew Energy Global (RNW) and Pampa Energía (PAM) both up 5%. DICE Therapeutics (DICE) shares rose 38% after Eli Lilly agreed to acquire the company.

Portfolio Pulse from Lisa Levin

June 20, 2023 | 1:52 pm

Eli Lilly has agreed to acquire biopharmaceutical company DICE Therapeutics for $2.4 billion. The acquisition will expand Lilly's pipeline with DICE's oral therapeutic candidates for immunology indications, including IL-17 inhibitors DC-806 and DC-853.

Portfolio Pulse from Vandana Singh

June 20, 2023 | 1:51 pm

Eli Lilly and Co (LLY) has agreed to acquire DICE Therapeutics (DICE) for $48 per share in cash. The transaction has been approved by both companies' boards and is expected to close in Q3. DICE's stock price soared, hitting new 52-week highs.

Portfolio Pulse from Adam Eckert

June 20, 2023 | 1:18 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.